Avanos Medical, announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a privately held company based in Raleigh, NC.
This transaction aligns with Avanos’ ongoing transformation, which is focused on advancing its strategic segments in Pain Management & Recovery and Specialty Nutrition Systems.
Health Technology Insights: Proprio Joins the AWS Partner Network
The divested portfolio includes the TriVisc and GenVisc 850 injection products, which are indicated for the treatment of osteoarthritis (OA) pain in the knee. These injectable HA therapies are designed to help patients manage OA symptoms and improve joint function.
“This divestiture represents a meaningful step in advancing our transformation strategy and reinforcing our commitment to focused growth,” said Dave Pacitti, Avanos’ chief executive officer. “By aligning our product portfolio more closely with our strategic priorities, we expect to strengthen our ability to invest in those areas where we see the greatest potential to lead, innovate, and deliver long-term value for patients, customers, and shareholders.”
Health Technology Insights: DXC Assure Risk Management Launches AI Claims Solution
Channel-Markers Medical specializes in the development and commercialization of joint health, regenerative therapies, and minimally invasive pain management solutions. The acquisition of the HA portfolio supports CMM’s strategic goal to expand its presence in musculoskeletal health and injectable pain therapies.
With today’s announcement, ownership of Avanos’ HA product line has officially transferred to CMM. Avanos will provide transition support through the end of 2025 to ensure uninterrupted service and support for customers, partners, and patients.
“This acquisition aligns with our mission to deliver high-quality, clinically proven therapies that improve patient mobility and quality of life,” said David Toledo, one of CMM’s managing partners. “We’re proud to integrate these trusted brands into our portfolio as we accelerate our growth in the pain therapy market.”
Health Technology Insights: Panome Bio Multi-omics Laboratory Enhances Clinical Capabilities with CLIA Certification
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
